General Information of Drug (ID: DMH6NG5)

Drug Name
FENDILINE Drug Info
Synonyms
fendiline; Fendilin; 13042-18-7; Fendilinum; Fendilinum [INN-Latin]; Fendilina [INN-Spanish]; Fendiline [INN]; EINECS 235-915-6; CHEMBL254832; Fendiline (INN); Benzenepropanamine, gamma-phenyl-N-(1-phenylethyl)-; Benzenepropanamine, .gamma.-phenyl-N-(1-phenylethyl)-; 3,3-diphenyl-N-(1-phenylethyl)propan-1-amine; Phendilin; Fendilina; Senzit; NCGC00018223-06; SPBio_001131; Spectrum_000443; AC1L1FPB; Spectrum5_001302; Spectrum2_001006; Prestwick1_000270; Spectrum4_000417; Prestwick3_000270; Spectrum3_001436; Prestwick2_000270
Indication
Disease Entry ICD 11 Status REF
Coronary artery disease BA80 Withdrawn from market [1]
Cross-matching ID
PubChem CID
3336
ChEBI ID
CHEBI:94434
CAS Number
CAS 13042-18-7
TTD Drug ID
DMH6NG5
VARIDT Drug ID
DR00949
INTEDE Drug ID
DR0686

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 2B receptor (HTR2B) TT0K1SC 5HT2B_HUMAN Inhibitor [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID Highest Status REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Phase 4 [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
5-HT 2B receptor (HTR2B) DTT HTR2B 0.485 3.536 0.379 4.667
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 11.692 6.58 4.984 9.089
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Coronary artery disease
ICD Disease Classification BA80
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
5-HT 2B receptor (HTR2B) DTT HTR2B 2.08E-01 -0.05 -0.23
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 6.06E-01 -2.42E-02 -1.64E-01
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Value of fendiline in the treatment of patients with stable angina pectoris. Pol Tyg Lek. 1987 Nov 16;42(46):1456-8.
2 Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify no... J Med Chem. 2010 Nov 11;53(21):7573-86.
3 Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.